ATE426412T1 - Adjuvante influenza-vakzine - Google Patents

Adjuvante influenza-vakzine

Info

Publication number
ATE426412T1
ATE426412T1 AT04706554T AT04706554T ATE426412T1 AT E426412 T1 ATE426412 T1 AT E426412T1 AT 04706554 T AT04706554 T AT 04706554T AT 04706554 T AT04706554 T AT 04706554T AT E426412 T1 ATE426412 T1 AT E426412T1
Authority
AT
Austria
Prior art keywords
influenza vaccine
adjuvant influenza
compositions
adjuvant
relates
Prior art date
Application number
AT04706554T
Other languages
English (en)
Inventor
Derek O'hagan
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE426412T1 publication Critical patent/ATE426412T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04706554T 2003-01-30 2004-01-29 Adjuvante influenza-vakzine ATE426412T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44398503P 2003-01-30 2003-01-30

Publications (1)

Publication Number Publication Date
ATE426412T1 true ATE426412T1 (de) 2009-04-15

Family

ID=32927453

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04706554T ATE426412T1 (de) 2003-01-30 2004-01-29 Adjuvante influenza-vakzine

Country Status (7)

Country Link
US (1) US20050106178A1 (de)
EP (1) EP1594536B1 (de)
JP (1) JP4675317B2 (de)
AT (1) ATE426412T1 (de)
CA (1) CA2514667C (de)
DE (1) DE602004020189D1 (de)
WO (1) WO2004075829A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20080254065A1 (en) * 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
AU2005334819B2 (en) * 2004-11-15 2011-11-24 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
CA2593176A1 (en) * 2005-01-05 2006-07-13 Peter D. Katsikis Delivery vehicles, bioactive substances and viral vaccines
US7572620B2 (en) * 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
PE20061428A1 (es) 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
US20100158943A1 (en) * 2005-11-04 2010-06-24 Novartis Vaccines And Diagnostics Srl Administration routes for priming/boosting with influenza vaccines
PT1951300E (pt) * 2005-11-04 2011-09-05 Novartis Vaccines & Diagnostic Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
JP2009514536A (ja) * 2005-11-07 2009-04-09 シドニー キンメル キャンサー センター Ｃｄ４０リガンド融合蛋白質ワクチン
AU2007221154A1 (en) * 2006-02-24 2007-09-07 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
WO2008039390A2 (en) * 2006-09-22 2008-04-03 Government Of The Usa., Dept. Of Health & Human Services Compositions and methods for chitosan enhanced immune response
SG10202012986SA (en) * 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
KR100874256B1 (ko) 2007-02-12 2008-12-16 대한민국 대장균 내독소 단백질 및 뉴캐슬병 바이러스뉴라미니데이즈 에피토프의 융합단백질 및 이의 용도
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EP2772267B1 (de) * 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogene Zusammensetzungen und Verfahren
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN101918028B (zh) 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20110223195A1 (en) * 2008-09-05 2011-09-15 Ceva Sante Animale Sa Composition comprising chitosan for ocular administration of vaccine(s) to avians
US9278126B2 (en) 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
US20120237545A1 (en) * 2009-05-29 2012-09-20 Norvartis Ag Assays for influenza virus hemagglutinins
TW201103980A (en) * 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
JP2013520172A (ja) * 2010-02-18 2013-06-06 モウント シナイ スクール オフ メディシネ インフルエンザウイルス疾患の予防及び治療で用いるためのワクチン
WO2011114346A1 (en) 2010-03-18 2011-09-22 Chetan Balar Chitin and related compounds for use in treating bacterial and viral infections
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
MX356586B (es) 2011-07-11 2018-06-05 Takeda Vaccines Inc Formulaciones parenterales de vacunas contra los norovirus.
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
EP2934581B1 (de) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenzavirus-impfstoffe und verwendungen davon
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
EP3471767A4 (de) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenzavirus-hämagglutinin-proteine und verwendungen davon
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
EP3810634A4 (de) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaik-influenzavirus-hämagglutinin-polypeptide und deren verwendungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO2000056362A2 (en) * 1999-03-24 2000-09-28 The Secretary Of State For Defence Polycationic carbohydrates as immunostimulants in vaccines
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20020165176A1 (en) * 2000-05-01 2002-11-07 Haynes Joel R. Nucleic acid immunization
WO2001098206A1 (en) * 2000-06-22 2001-12-27 Rxkinetix, Inc. Delivery vehicle composition and methods for delivering antigens and other drugs
AU2002334844B2 (en) * 2001-10-03 2007-08-02 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery

Also Published As

Publication number Publication date
JP4675317B2 (ja) 2011-04-20
EP1594536A4 (de) 2006-09-06
DE602004020189D1 (de) 2009-05-07
CA2514667C (en) 2013-01-08
US20050106178A1 (en) 2005-05-19
CA2514667A1 (en) 2004-09-10
WO2004075829A2 (en) 2004-09-10
EP1594536B1 (de) 2009-03-25
EP1594536A2 (de) 2005-11-16
JP2006516638A (ja) 2006-07-06
WO2004075829A3 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
ATE426412T1 (de) Adjuvante influenza-vakzine
PL375398A1 (en) Immunostimulatory nucleic acids
DK1545597T3 (da) Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2007067681A3 (en) Immunostimulatory compositions and methods
WO2004030608A3 (en) Nanoemulsion vaccines
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
WO2006091915A3 (en) Immunostimulatory oligonucleotides
DK1487485T3 (da) Imidazoquinolinadjuvanser til DNA-vacciner
DK1635863T3 (da) Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
NO20070699L (no) Spesielle aminoalkylglukosaminidfosfatforbindelser og deres anvendelse
MY165643A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
BRPI0520330B8 (pt) adjuvante a base de ácido polinosínico-policitidílico
ATE412649T1 (de) Substituierte heteroarylbenzofuransäuren
DE60330708D1 (de) Impfstoff gegen das west-nile-virus
GB2386072A (en) Novel vaccine
CY1110744T1 (el) Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
DE60226175D1 (de) Mycobakterieller impfstoff
PL380950A1 (pl) Pewne związki amionoalkiloglukozaminidofosforanowe i ich zastosowanie
NO20062579L (no) Preparater som omfatter melittin-avledede peptider og fremgangsmate for styrking av immunresponser mot malantigener
EA200301151A1 (ru) Вакцина против натуральной оспы
WO2007120860A3 (en) Nanoemulsion vaccines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties